Status:
RECRUITING
Research on the Safety and Efficacy of Blocking Dural Blood Supply in Glioblastoma Patients
Lead Sponsor:
First Affiliated Hospital, Sun Yat-Sen University
Conditions:
Glioblastoma
Meningeal Arteries
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Glioblastoma is the most common primary malignancy of the central nervous system with a very poor prognosis. Most of the immunotherapies that have made significant breakthroughs in the treatment of ot...
Eligibility Criteria
Inclusion
- Imaging or needle biopsy pathologically diagnosed as glioblastoma
- Patients have not previously received radiotherapy, chemotherapy and other treatment modalities for intracranial lesions
- There are no related contraindications such as neurovascular intervention and craniotomy
Exclusion
- The patient's initial imaging diagnosis was glioblastoma, and the postoperative pathology confirmed nonglioblastoma
- The patient has other underlying medical conditions that affect survival time
- The patient had other underlying medical conditions that affected follow-up or quality of life assessment
- Patients do not have the above exclusion criteria and refuse to participate in clinical trials after informed consent
Key Trial Info
Start Date :
May 11 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2028
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05990556
Start Date
May 11 2024
End Date
September 1 2028
Last Update
July 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
the First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China, 510000